10-Q: Cooper Companies Reports Strong Net Income Amidst Litigation

The Cooper Companies, Inc. announced its quarterly results, showcasing a significant increase in net income driven by a substantial tax benefit, while also disclosing a large litigation settlement impacting operating income.

Summary

• The Cooper Companies, Inc. reported net sales of $1,066.2 million for the three months ended July 31, 2026, a slight increase from $1,060.3 million in the prior year period.
• Net income for the three months ended July 31, 2026, surged to $432.8 million ($2.24 per diluted share), a significant increase from $98.3 million ($0.49 per diluted share) in the same period last year, largely due to a $307.2 million discrete income tax benefit.
• For the nine months ended July 31, 2026, net sales were $3,171.8 million, up from $3,027.3 million in the prior year.
• Net income for the nine months increased to $485.7 million ($2.49 per diluted share) from $290.3 million ($1.45 per diluted share) in the prior year, also benefiting from the tax release.
• Operating income for the three months was $222.0 million, up from $175.7 million, but the nine-month operating income decreased to $403.8 million from $542.5 million, impacted by a $272.0 million litigation expense.
• The company's CooperVision segment showed stable net sales for the quarter and growth for the nine months, while CooperSurgical saw modest growth in both periods.
• The company ended the quarter with $154.7 million in cash and cash equivalents and had $1,328.0 million available under its revolving credit facility.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive report, with strong net income growth driven by a significant tax benefit, though offset by a substantial litigation charge impacting operating income in one segment.

Positives

• Net income for the three months ended July 31, 2026, increased significantly to $432.8 million from $98.3 million in the prior year.
• Diluted earnings per share for the three months rose to $2.24 from $0.49 in the prior year.
• Net income for the nine months ended July 31, 2026, increased to $485.7 million from $290.3 million in the prior year.
• Diluted earnings per share for the nine months rose to $2.49 from $1.45 in the prior year.
• A significant discrete income tax benefit of $307.2 million was recognized in the current period related to the favorable resolution of a tax authority examination.
• Consolidated gross margin improved to 67% for the three months and 68% for the nine months, up from 65% and 67% respectively in the prior year, primarily due to the absence of inventory write-offs seen in the prior year.
• CooperVision's operating income increased by 1% for the three months and 10% for the nine months.
• The company has substantial liquidity with $154.7 million in cash and cash equivalents and $1,328.0 million available under its revolving credit facility.

Negatives

• CooperSurgical reported an operating loss of ($157.1) million for the nine months ended July 31, 2026, compared to an operating income of $39.7 million in the prior year, primarily due to a $272.0 million litigation expense.
• The company incurred a significant litigation expense of $272.0 million, net of insurance recoveries, related to the recall of CooperSurgical's LifeGlobal™ embryo culture media.
• CooperVision's net sales in Asia Pacific declined by 10% for the three months and 7% for the nine months.
• CooperVision's net sales in the Americas declined by 2% for the three months, attributed to reductions in U.S. channel inventory.
• The company's working capital decreased significantly to $414.9 million from $993.6 million, primarily due to an increase in short-term debt.

Risks

• Adverse changes in global macroeconomic conditions, political instability, natural disasters, and pandemic conditions could negatively impact global markets and the company's performance.
• International conflicts, such as the one in the Middle East, and global responses to them can affect financial markets, energy prices, currency rates, and the company's ability to supply products.
• Managing extensive international operations and complying with diverse legal and regulatory requirements presents challenges.
• Tariffs, trade protection measures, and other trade barriers imposed by governments can impact operations and require mitigation efforts.
• Fluctuations in foreign currency exchange rates and interest rates can decrease net sales and earnings.
• Existing and future variable rate indebtedness could be adversely affected by interest rate increases, potentially limiting borrowing capacity.
• Changes in tax laws, tax authority examinations, and shifts in the geographic composition of income pose risks.
• Acquisition-related risks include failure to achieve expected benefits, integration delays, accounting adjustments, regulatory hurdles, increased leverage, and financing difficulties.

Future Outlook

The company expresses optimism about the long-term prospects for the worldwide contact lens and general healthcare markets, citing resilience and growth potential. However, it acknowledges significant risks and uncertainties in the global operating environment, including macroeconomic conditions, geopolitical instability, foreign exchange fluctuations, regulatory developments, supply chain disruptions, and trade barriers, which have adversely affected and could continue to affect future sales, cash flow, and performance.

Management Comments

• We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products.
• However, we face significant risks and uncertainties in our global operating environment as further described in the Part II, Item 1A 'Risk Factors' herein.
• Our ability to compete successfully with a full range of silicone hydrogel products is an important factor to achieving our desired future levels of sales growth and profitability.

Industry Context

StockSavvy.ai notes that The Cooper Companies operates in two distinct but complementary sectors: contact lenses (CooperVision) and fertility/women's health (CooperSurgical). The contact lens market is characterized by technological advancements in materials and designs, with a shift towards single-use modalities and growth in myopia management. The fertility and women's health market is driven by scientific advances, product quality, and a diversified portfolio. The company's performance reflects trends in both these dynamic healthcare sub-sectors.

Comparison to Industry Standards

• The Cooper Companies' gross margin of 67-68% for the nine-month period is strong, particularly in the medical device and healthcare sectors, where margins can vary significantly based on product complexity and R&D investment.
• The company's net sales growth of 5% for CooperVision and 4% for CooperSurgical over nine months is generally in line with or slightly above the projected growth rates for the global contact lens market (estimated 4-6%) and the broader women's health market, which can see higher growth in specific segments like fertility.
• The significant litigation charge impacting CooperSurgical's operating income highlights a risk common in the medical device and pharmaceutical industries, where product recalls and associated liabilities can occur. Companies like Johnson & Johnson (e.g., talc litigation) and Bayer (e.g., Essure litigation) have faced substantial legal costs, making Cooper Companies' $272 million charge a notable, though not unprecedented, event in this context.

Legal Proceedings

• The Company is involved in a dispute with HM Revenue & Customs (HMRC) concerning payroll tax withholding on consideration paid for the Sauflon Group acquisition in 2014. The UK First-tier Tribunal (FTT) largely supported HMRC's position. The Company is appealing this decision, with a potential estimated loss ranging from 0 to £71.7 million plus interest.
• Following a voluntary recall of CooperSurgical's LifeGlobal™ global embryo culture media in December 2023, numerous claims and lawsuits were filed alleging damages such as embryo loss. As of June 5, 2026, over 140 lawsuits were filed, including three putative class actions, and over 1,500 claimants were proffered. The company concluded a loss was probable and estimable, resulting in a $272.0 million net impact to operations for the nine months ended July 31, 2026, including a $325.8 million accrued litigation liability offset by $53.8 million in insurance recoveries. A settlement of substantially all claims was paid in August 2026.

Stakeholder Impact

• Shareholders benefit from the significant increase in net income and diluted EPS, driven by operational performance and a substantial tax benefit.
• The substantial litigation settlement may impact future cash flows and liquidity, potentially affecting shareholder returns or future investment capacity.
• Employees may be impacted by headcount reductions mentioned in SGA expense discussions for CooperVision and CooperSurgical.
• Customers in the Asia Pacific region for CooperVision experienced sales declines, potentially indicating market challenges or competitive pressures affecting them.
• Suppliers may be affected by the company's inventory management and potential product line exits.

Next Steps

• The company will continue to focus on greater worldwide market penetration for CooperVision using recently introduced products and expanding its presence in existing and emerging markets, including through acquisitions.
• CooperVision will focus on its single-use silicone hydrogel product franchises (clariti, MyDay, MyDay Energy) and its Biofinity and Avaira Vitality product families in the FRP market.
• CooperSurgical will continue to develop products and acquire companies, products, and services that complement its business model in fertility and women's health.
• The company is evaluating the impact of newly issued accounting standards on its financial statements.
• The company is appealing the FTT's decision regarding the Sauflon Group payroll tax dispute.

Key Dates

Recommendation

The company delivered strong net income growth driven by a significant one-time tax benefit, which masks underlying operational pressures in CooperSurgical due to a large litigation settlement. While CooperVision shows stable performance, the substantial litigation charge and its impact on operating income, coupled with risks in international markets, warrant a cautious approach. The significant share repurchase authorization provides some support, but the overall picture suggests holding the stock until the impact of the litigation is fully absorbed and operational trends become clearer.

Keywords

contact lenses, fertility, women's health, medical devices, cryostorage, myopia management, embryo culture media, litigation